Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD

NCT ID: NCT00585299

Last Updated: 2014-06-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess whether reversal of fatty liver by moderate weight loss (8% of body weight) will lead to improvements in insulin sensitivity, which will be associated with changes in both glucose status and lipid profiles, in obese children and adolescents with fatty liver who have normal glucose or pre-diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will have two groups: one group that eats a moderate calorie, low-fat diet and is weighed regularly (every other week for 16 weeks) and the other who receives traditional diet therapy and returns in 16 weeks. Both groups will undergo procedures that test glucose tolerance and measure liver and muscle fat content before and after study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatty Liver Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-fat diet

20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week

Group Type EXPERIMENTAL

Low-fat diet

Intervention Type OTHER

20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks

Traditional diet

Intervention Type OTHER

Traditional low-fat diet with dietitian follow-up in 16 weeks

Traditional

Traditional low-fat diet given and dietitian follows up in 16 weeks

Group Type ACTIVE_COMPARATOR

Traditional diet

Intervention Type OTHER

Traditional low-fat diet with dietitian follow-up in 16 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low-fat diet

20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks

Intervention Type OTHER

Traditional diet

Traditional low-fat diet with dietitian follow-up in 16 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 10 to 21 yrs of age
* Non-smoking
* BMI \>95th percentile for age and gender, but BMI \<40
* Suspicion of fatty liver, with a high ALT (\>35)
* Normal glucose tolerance or prediabetes (impaired glucose tolerance or impaired fasting glucose)

Exclusion Criteria

* Females of child-bearing potential who are not using birth control
* Pregnant or lactating females
* Current medications except oral anti-diabetic medications and hormonal birth control
* Lipid-lowering medication that increases liver enzymes
* Significant kidney dysfunction (creatinine \>1.5 mg/dL)
* Current heavy ethanol use or recent history of binge drinking
* History or evidence of hepatitis A, B, or C, Wilson's Disease, or alpha-1-antitrypsin deficiency
* Known to be HIV positive
* Symptomatic angina pectoris or cardiac insufficiency as defined by the NYHA classification as Functional Class III or IV
* Major vascular event within 6 months of screening (e.g. MI, stroke)
* Active cancer within 5 years prior to screening
* Current systemic disease, including type 1 or 2 diabetes
* Enrolled in another research study within 1 month prior to screening
* Implanted paramagnetic material (all subjects will need to fill out the Yale Magnetic Resonance Center safety checklist)
* Anemia (HCT \<35%)
Minimum Eligible Age

10 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sonia Caprio, MD

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01HD040787-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

0212023115

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.